Results are available as preprint and have been submitted in an international peer-reviewed journal. https://www.biorxiv.org/content/10.1101/2022.04.01.486719v1 SpikImm expects to initiate
Truffle Capital & The Institut Pasteur Create SpikImm to Develop Monoclonal Antibodies as an Innovative Treatment For Covid-19
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005708/en/
Monoclonal antibody therapy is one of the most innovative ways currently available to treat Covid-19 patients and prevent severe forms of the disease from developing. This immunotherapy offers several therapeutic advantages which have already been proven in clinical trials. Antibodies developed by SpikImm have been generated in the laboratory of Humoral Immunology at the Institut Pasteur through an innovative process enabling the screening and selection of human SARS-CoV-2 neutralizing antibodies. An international patent application has been filed by the Institut Pasteur.